Fig. 2

Frequency (%) (a) and absolute number (Cell/μl) (b) of peripheral regulatory CD25^bright/CD127^low CD4⁺ T cells in total leukocytes, from healthy individuals (HG) and heart failure patients, at baseline assessment (HFP-T0) and 6 months after cardiac resynchronization therapy implantation (HFP-T6). Heart failure patients were distributed: according to response to cardiac resynchronization therapy: responders (R) and non-responders (NR). Statistically significant differences were considered when P < 0.05